In 2019, China will implement zero tariff on raw materials for multi drug production

[China Pharmaceutical network industry trends] recently, the Ministry of Finance disclosed that China will adjust the import and export tariffs of some commodities in 2019 Among them, China will implement provisional import tax rates for more than 700 goods, including the implementation of zero tariff for various pharmaceutical raw materials Among them, the newly added raw materials for drug production include more than 50 kinds of anti-cancer drug raw materials, such as triptoreline acetate, formetan, exemestane, vinorelbine tartrate, vincristine sulfate, topotecan hydrochloride and irinotecan hydrochloride, with the tax rate reduced from 4% to 0; the tax rate of lenalidomine, the anti-cancer drug raw material, has been reduced from 9% to 0 In addition, the tax rate of penicillamine, riluzole and bosentan, the raw materials of rare disease drugs, was directly reduced from 6.5% to 0, while that of pirfenidone, the raw materials of rare disease drugs, was directly reduced from 9% to 0 In addition, the tax rate of antiserum, other blood points, immune products, human vaccines and other medical products was reduced from 3% to 0 It is well known that the raw materials for drug production are raw materials However, in recent years, the surge of APIs in China has led to the soaring cost of drug production, and the price of drugs has to be increased Besides monopoly, the reason behind the price rise of API is that there are few raw material manufacturers and the supply is in short supply In this context, China's monopoly and market continue to improve In view of the shortage of APIs in China, some experts have suggested that some raw materials can be imported from abroad to alleviate the domestic shortage It is understood that lenalidomide used in the treatment of multiple myeloma in the United States has been listed in China, but the price of imported lenalidomide is close to the sky high price, which is difficult for many patients to afford for a long time According to the content of this disclosure, there will be zero tariff for more than 50 kinds of anti-cancer drug raw materials next year, which will further reduce the price of anti-cancer drugs The tax rate of lenalidomine, the raw material of anticancer drugs, has been directly reduced from 9% to 0, which is expected to reduce the cost of domestic generic pharmaceutical enterprises and realize product price reduction In addition, it will also attract foreign original manufacturers to set up branches in China to produce and sell related drugs, and the product is also expected to reduce the price In fact, since this year, the policy of adjusting the price reduction of domestic anti-cancer drugs has been uninterrupted For example, since May 1 this year, China has decided to implement zero tariff on imported anti-cancer drugs Among them, the notice on provincial special centralized procurement of anticancer drugs issued by the National Health Insurance Bureau and the National Health Commission made it clear in the draft for comments that by the end of August 2018, each province will issue the implementation plan for provincial special centralized procurement of anticancer drugs; by the end of September, the procurement work will be started in an all-round way, and by the end of the year, the special centralized procurement work will be completed, including online, procurement, use monitoring and final The end prices are all in place to benefit patients In this context, Beijing, Yunnan, Anhui, Shanxi, Inner Mongolia, Liaoning and other places have launched anti-cancer drug procurement On November 1, the national catalogue of essential drugs (2018 Edition) was officially implemented, in which 12 new anticancer drugs were added to the adjusted catalogue of essential drugs, including some innovative drugs such as small molecule targeted drugs In addition, favorable policies such as accelerating the approval of new drugs, centralized procurement through negotiation, inclusion in the medical insurance reimbursement catalogue, and accelerating the import and listing of innovative drugs have been successively issued, which have brought many benefits to cancer patients It is reported that the average price reduction of cancer drugs is 56.7% In general, in 2019, the price of anti-cancer drugs in China is expected to further reduce, which is undoubtedly a good news for more than 3 million cancer patients in China every year.